LAS VEGAS, Nov. 15, 2017 — GB Sciences, Inc. (OTCQB: GBLX) announces that it has exceeded the October gross revenue projection of $500K from the sale of premium flower by 2%. Gross sales projections for the month of November are also trending in this direction.

The GB Sciences cultivation facility has 180 active flower lights for plant cultivation and grows in a clean room-like environment. The industry standard yield is approximately one and one-half (1.5) pounds yield per flower light (of cured, untrimmed flower).  GB Sciences yield is about three pounds of yield per flower light. 

The COO Kevin Kuethe explains, “Our state-of-the-art modern growing facility and techniques create and control the growing environment.  Inside that environment, our growers bring a deep experience and understanding of the plant.  The combination of a state-of-the-art precision growing environment and having a dedicated and harmonious team operate that environment, enables us to consistently produce yields that are double the industry average.”

Kevin Kuethe added, “Our custom concentrated nutrient blends are a key element in the process.  After all, it is the nutrition that keeps the plants healthy, and each strain eats a little different blend of nutrients to maximize the genetic potential of each of our strains.  Because we measure and monitor the exact amounts of every aspect of the plant's life, we can scientifically determine how to maximize the yields.  We operate our precision controlled growing environments for maximum consistency, quality and yield.”

GB Sciences, Inc.
GB Sciences, Inc. (GBLX) is a diverse cannabis company, focused on standardized cultivation and production methods; as well as biopharmaceutical research and development. The Company's goal is creating safe, standardized, pharmaceutical-grade, cannabinoid therapies that target a variety of medical conditions. To learn more about GB Sciences, Inc., go to: http://gbsciences.com.

Forward-Looking Statements
This press release may contain statements relating to future results or events, which are forward-looking statements.  Words such as “expects”, “intends”, “plans”, “may”, “could”, “should”, “anticipates”, “likely”, “believes” and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control.  It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements.  Further, information concerning the Company and its business, including factors that potentially could materially affect the Company's business and financial and other results, are contained in the Company's filings with the Securities and Exchange Commission, available at www.sec.gov.  All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.
Note:  Although the Company's research and development activities are not illegal, the production and sale of cannabis products violate federal laws as they presently exist.

Contact Information
Corporate:
GB Sciences, Inc., 3550 West Teco Ave., Las Vegas, NV 89118
1-866-721-0297, or http://gbsciences.com
Tom Arcuragi, Sr VP Marketing, [email protected]

View original content with multimedia:http://www.prnewswire.com/news-releases/gb-sciences-exceeds-its-gross-revenue-projections-for-october-doubles-the-industry-average-yield-per-active-flower-light-300556141.html

SOURCE GB Sciences, Inc.

Related Links

http://gbsciences.com

Powered by WPeMatico